Roche Holding AG reported revenue of CHF 59.497 billion for the FY 2018 which saw an increase of 6.73% compared to FY 2017. Roche revenue is expected to increase by 5% and reach CHF 62.472 billion by FY 2019. Roche Holding AG registered highest revenue from United States market at including royalties which accounted for 47.20% of its total sales in FY 2018.

Johnson & Johnson is the largest healthcare company by revenue which generated a whopping USD 81.58 billion in total sales in 2018, and pharmaceuticals franchise were responsible for more than 50% of the conglomerate's top line. In 2018, annual consumer care franchise rose just 1.8% and the medical device segment generated a marginal 1.5% gain. Quite evidently, Johnson & Johnson's pharmaceutical run the show and pushed total revenue to 7% higher last year.

Sanofi’s fourth-quarter business net income was up 4.3 percent at constant exchange rates to 1.36 billion euros, while revenue rose 3.9 percent to 9 billion. Sales at Genzyme surged 37.4 percent. Net sales in 2018 were €34,463 million, down 1.7% according to latest report. The decline is mainly due to diabetes and cardiovascular (DCV) business unit performance as unit sales were down by 11.3%.Sanofi’s fourth-quarter business net income was up 4.3 percent at constant exchange rates to 1.36 billion euros, while revenue rose 3.9 percent to 9 billion.

Merck reported revenue of USD 42.294 billion for the FY 2018 which saw an increase of 5.41% compared to FY 2017. This revenue is expected to increase by 5.68% and reach USD 44.700 billion by FY 2019.Looking into 2019, Merck said it sees non-GAAP earnings of between $4.57 and $4.72 per share on worldwide sales of between $43.2 billion and $44.7 billion.

AbbVie Inc. reported revenue of USD 32.733 billion for the FY 2018 which saw an increase of 16% compared to FY 2017. Company's global sales were impacted by the launch of several direct biosimilar drugs. These drugs are launched at much cheaper price anticipated by AbbVie resulting decline in sales in Europe and other international markets.

Amgen's full year, total revenues increased 4 percent to $23.7 billion, with 3 percent product sales growth. Company's product sales grew 8 percent globally. New and recently launched products including Repatha® (evolocumab), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab) registered double-digit growth.

GlaxoSmithKline reported revenue of USD 40.992 billion for the FY 2018 which saw an increase of 4.46% compared to FY 2017. Consumer healthcare division had second largest revenue share with 24.85% revenue share. This division saw an increase of 1.09% compared to FY 2017 revenue.

Bristol-Myers Squibb reports 10% increase in their fourth quarter revenues which reached to $6.0 Billion, and 9% for Full Year to $22.6 Billion.U.S. revenues increased 16% to $3.3 billion in the quarter compared to the same period a year ago. International revenues increased 3%.